Summary of results

• Rapid effectiveness from 4 weeks against acute and chronic digestive disorders clinically proven.
• Reduction of diarrhea infectious and post-antibiotic, improvement of the constipation , bloating and IBS pain .
• THE three strains strengthen the intestinal barrier , regulate the microbiota And support local immunity .
• There probiotic synergy acts both curatively and preventively , with a very good clinical tolerance .
• THE results are validated by several clinical trials reference on each of the strains.

Clinical efficacy of the “Emergency intestinal crisis” formula and its probiotics

This highly dosed combination combines the 3 major strains most documented in acute and chronic intestinal disorders. They act synergistically on infectious diarrhea, post-antibiotic disorders, IBS, constipation and digestive discomfort, while strengthening the intestinal barrier and mucosal immunity.

Proven effectiveness from 4 weeks , risk-free, with a impeccable security profile .

✔ Bifidobacterium lactis – 40 billion CFU
Demonstrated clinical effects:

- Prevention of antibiotic-associated and infectious diarrhea (IAD):
Studies in children and adults have shown that B. lactis reduces the frequency, duration, and severity of post-antibiotic and infectious diarrhea (including viral gastroenteritis).
Mechanisms: inhibition of pathogenic bacterial adhesion, modulation of local immunity, improvement of epithelial integrity.

- Effect on intestinal transit and constipation:
Trials have shown that certain strains of B. lactis (e.g. HN019) accelerate colonic transit and increase stool frequency, particularly in constipated subjects or the elderly.
Mechanisms: stimulation of peristalsis, production of short-chain fatty acids.

- Immune strengthening:
B. lactis is a strain documented to strengthen intestinal immune defenses (IgA production), thus reducing digestive and respiratory infections.

✔ Lactobacillus acidophilus – 40 billion CFU
Demonstrated clinical effects:

- Reduction of bloating, abdominal pain and gas:
Particularly in the context of irritable bowel syndrome (IBS) and functional digestive disorders.
Mechanisms: modulation of the microbiota, reduction of excessive colonic fermentation, regulation of intestinal permeability.

- Anti-diarrheal effect:
Combined with other strains or alone, L. acidophilus reduces the duration and intensity of acute diarrhea (viral, bacterial).

-Support for the intestinal mucosa and protection of the intestinal barrier:
It increases mucus production, promotes mucosal healing and limits low-grade inflammation.

✔ Lactobacillus plantarum – 20 billion CFU
Demonstrated clinical effects:

- Improvement of symptoms of irritable bowel syndrome (IBS):
Several trials, including randomized trials, have shown that L. plantarum 299v effectively reduces abdominal pain, bloating and improves quality of life.
Mechanisms: regulation of visceral sensitivity, localized anti-inflammatory effect, normalization of the microbiota.

- Antimicrobial effects:
L. plantarum produces bacteriocins and directly inhibits pathogens such as E. coli, Salmonella, etc.

- Regulation of the intestinal immune system:
Stimulation of macrophages, regulation of pro-inflammatory cytokines and increase of mucosal defenses.

Synergy of these three strains together

- Broad spectrum protection against infectious diarrhea, IBD and IBS with dominant diarrhea.
- Improvement of bloating, post-prandial pain and gas.
- Regulation of intestinal transit in cases of
alternating constipation and diarrhea.
- Strengthening and protection of the digestive mucosa and intestinal permeability.
- Global immunomodulatory effect on the axis
gut-immunity.

In clinical practice:

- This set is suitable for all acute or chronic intestinal crises , whether of infectious origin, post-antibiotics, or in the context of functional intestinal disorders (IBS, bloating, digestive pain).
- Very well tolerated at high doses (>20 billion CFU/strain).
- Can be used in curative (acute diarrhea, IBS flare-ups) or in prevention (pre-ATB, stress, dietary changes) .

Studies:

- Ringel et al. , J Clin Gastroenterol L. acidophilus NCFM + B. lactis Bi-07 vs placebo for bloating pmc.ncbi.nlm.nih.gov

- Zhang et al. , Ann Transl Med L. plantarum Lp3a improves functional constipation pubmed.ncbi.nlm.nih.gov

- Cheng et al. , JAMA Netw Open B. lactis HN019 on functional constipation: RCT pubmed.ncbi.nlm.nih.gov

- Ibarra et al. , Gut Microbes 28 d B. lactis HN019 at FC pubmed.ncbi.nlm.nih.gov